1. Home
  2. TCPC vs NMRA Comparison

TCPC vs NMRA Comparison

Compare TCPC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock TCP Capital Corp.

TCPC

BlackRock TCP Capital Corp.

HOLD

Current Price

$3.25

Market Cap

280.2M

Sector

Finance

ML Signal

HOLD

Logo Neumora Therapeutics Inc.

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

311.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCPC
NMRA
Founded
2006
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
280.2M
311.3M
IPO Year
2006
2023

Fundamental Metrics

Financial Performance
Metric
TCPC
NMRA
Price
$3.25
$1.61
Analyst Decision
Sell
Buy
Analyst Count
2
8
Target Price
$3.50
$7.50
AVG Volume (30 Days)
874.8K
3.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
18.23%
N/A
EPS Growth
N/A
5.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.08
$0.83
52 Week High
$7.74
$3.65

Technical Indicators

Market Signals
Indicator
TCPC
NMRA
Relative Strength Index (RSI) 42.49 47.68
Support Level $3.10 $1.53
Resistance Level $3.54 $2.00
Average True Range (ATR) 0.12 0.11
MACD 0.02 0.01
Stochastic Oscillator 27.38 18.64

Price Performance

Historical Comparison
TCPC
NMRA

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: